Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) EBITDA (2020 - 2025)

HCW Biologics (HCWB) has disclosed EBITDA for 6 consecutive years, with -$3.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 10.65% year-over-year to -$3.3 million, compared with a TTM value of -$11.9 million through Sep 2025, up 68.0%, and an annual FY2024 reading of -$29.5 million, down 14.63% over the prior year.
  • EBITDA was -$3.3 million for Q3 2025 at HCW Biologics, up from -$3.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.9 million in Q1 2022 and bottomed at -$15.1 million in Q2 2024.
  • Average EBITDA over 5 years is -$4.9 million, with a median of -$3.7 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 235.57% in 2024, then surged 77.25% in 2025.
  • Year by year, EBITDA stood at -$3.1 million in 2021, then tumbled by 82.08% to -$5.7 million in 2022, then tumbled by 90.01% to -$10.8 million in 2023, then skyrocketed by 70.6% to -$3.2 million in 2024, then decreased by 4.0% to -$3.3 million in 2025.
  • Business Quant data shows EBITDA for HCWB at -$3.3 million in Q3 2025, -$3.4 million in Q2 2025, and -$2.0 million in Q1 2025.